Best DNA Tests for Health: A Complete Buyer's Guide

The Five Categories of DNA Health Tests

Before comparing individual providers, it helps to understand the landscape. Genetic health tests fall into five categories, each serving different needs:

1. Consumer Direct-to-Consumer (DTC) Genotyping

Example: 23andMe Health + Ancestry ($199). These tests use genotyping chips to check 600,000–700,000 SNPs. 23andMe's FDA-authorized health reports cover 10+ conditions including BRCA1/BRCA2 (3 variants), hereditary thrombophilia, late-onset Alzheimer's (APOE), Parkinson's disease (LRRK2, GBA), and hereditary hemochromatosis. Reports are generated automatically, and genetic counseling support is limited to online resources. The key advantage: accessibility and no physician requirement. The key limitation: extremely narrow scope. 23andMe's BRCA report tests 3 variants out of more than 4,000 known — missing ~90% of carriers in non-Ashkenazi populations.

2. Physician-Mediated DTC Testing

Example: Color Health ($249). Color operates a hybrid model: you order the test online, but a network physician reviews and orders it, and results include access to board-certified genetic counselors. Color's test covers 30 genes associated with hereditary cancer (including all BRCA1/BRCA2 variants, Lynch syndrome genes, and others) and hereditary heart conditions (cardiomyopathies, arrhythmias, familial hypercholesterolemia). Color uses CLIA-certified, CAP-accredited lab processing and reports only clinically actionable variants. The key advantage: clinical-grade testing with consumer convenience and built-in genetic counseling. The key limitation: still panel-based, not comprehensive coverage.

3. Whole Genome Sequencing (Consumer)

Examples: Nebula Genomics ($299–$999), Dante Labs ($499–$599). WGS reads all 3 billion base pairs and can be re-analyzed indefinitely as new gene-disease associations are discovered. Nebula's platform provides automated annotation across thousands of traits, diseases, and pharmacogenetic markers. Reports update periodically with new research findings. The key advantage: future-proof, comprehensive, one-time investment. The key limitation: overwhelming data volume, automated (not clinician-reviewed) interpretation, and potential for false positives in DTC raw data files (40% false positive rate in DTC raw data per a 2020 Genetics in Medicine study).

4. Clinical Diagnostic Testing

Examples: Invitae, GeneDx, Ambry Genetics, Baylor Genetics. These are physician-ordered tests processed in CLIA-certified, CAP-accredited labs with interpretation by board-certified molecular geneticists. Testing ranges from single-gene tests to large panels (500+ genes) to clinical whole exome and whole genome sequencing. Results are confirmed by orthogonal methods before reporting. The key advantage: highest standard of evidence, clinical-grade reporting suitable for medical decision-making, insurance coverage often available. The key limitation: requires physician involvement, higher cost ($250–$5,000+), often requires meeting clinical criteria.

5. Pharmacogenetic (PGx) Testing

Examples: GeneSight, Genomind, Tempus, OneOme. Pharmacogenetic tests analyze genes that affect drug metabolism, transport, and targets — primarily CYP450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5), drug transporters (SLCO1B1), and drug targets (VKORC1, HLA-B). GeneSight's psychotropic panel covers 57 medications for depression, anxiety, ADHD, and other psychiatric conditions. Genomind covers 24 genes across psychiatric and general medications. The key advantage: directly actionable results that can guide medication selection and dosing today. The key limitation: most insurers only cover specific drug-gene pairs; cost without insurance is $330–$2,000.

Provider Comparison Table

FDA Oversight and Authorization: What It Actually Means

The FDA's role in genetic testing is widely misunderstood. The agency broadly divides genetic tests into two categories:

• FDA-Authorized Tests: These have undergone FDA review of analytical and clinical validity for specific claims. 23andMe's health reports are the most prominent example — the FDA has authorized their reports for specific conditions after reviewing evidence that the genotyping chip accurately detects the relevant variants and that the variants are associated with the claimed conditions. However, FDA authorization does not mean the test is comprehensive; 23andMe's BRCA report is authorized but tests only 3 variants.
• Laboratory-Developed Tests (LDTs): Most clinical genetic tests, including those from Invitae, Ambry, and GeneDx, fall into this category. These are developed and validated by individual CLIA-certified labs, regulated under CMS through CLIA rather than the FDA. In May 2024, the FDA finalized a rule to phase in oversight of LDTs over four years, bringing these tests under FDA authority by 2028.

The practical takeaway: FDA authorization is a useful quality signal but not the only one. CLIA certification, CAP accreditation, and professional guidelines (ACMG, NCCN, ACOG) are equally important markers of test quality.

GINA and Your Legal Protections

The Genetic Information Nondiscrimination Act of 2008 (GINA) provides federal protection against genetic discrimination. Under GINA, health insurers cannot use genetic information to deny coverage or set premiums, and employers with 15+ employees cannot use genetic information in hiring, firing, or promotion decisions.

However, GINA has significant gaps. It does not apply to:

• Life insurance
• Disability insurance
• Long-term care insurance
• Employers with fewer than 15 employees
• The US military (though separate policies exist)

Florida passed a law in 2020 (HB 1189) banning genetic discrimination in life insurance — the first state to do so. Several other states are considering similar legislation. If these protections matter to you, consider your insurance profile before testing.

Frequently Asked Questions